Notice of Annual General Meeting/Proxy Form
Released
Released
Announcement PDF
AVECHO BIOTECHNOLOGY LIMITED
ACN 056 482 403
Notice of Annual General Meeting
Explanatory Statement and Proxy Form
Date of Meeting:
Monday, 31 May 2021
Time of Meeting:
1.00pm (AEST)
Place of Meeting:
Grant Thornton Australia Limited
Level 22 Tower 5
Collins Square
727 Collins Street
Melbourne, VIC 3008
This Notice of Annual General Meeting and Explanatory Statement should be read in its entirety.
If Shareholders are in doubt as to how they should vote, they should seek advice from their accountant,
solicitor, or other professional advisor without delay.
AVECHO BIOTECHNOLOGY LIMITED
ACN 056 482 403
Registered Office: Unit A8, 2A Westall Road, Clayton, VIC 3168
NOTICE OF ANNUAL GENERAL MEETING
Notice is hereby given that the Annual General Meeting (AGM / Meeting) of shareholders of Avecho Biotechnology
Limited (the Company) will be held at Grant Thornton Australia Limited, Level 22 Tower 5, Collins Square, 727
Collins Street, Melbourne VIC 3008 on Monday, 31 May 2021 at 1.00pm (AEST).
AGENDA
The Explanatory Statement and Proxy Form which accompany and form part of this Notice, including defined terms
and describe in more detail the matters to be considered. Please consider this Notice, the Explanatory Statement,
and the Proxy Form in their entirety.
ORDINARY BUSINESS
Receipt and Consideration of Financial Statements and Reports
To receive and consider the Financial Report of the Company, together with the Directors’ Report (including the
Remuneration Report) and the Auditors’ Report for the year ended 31 December 2020.
Note: Except as set out in Resolution 1, there is no requirement for Shareholders to vote on a resolution or adopt
these reports. Accordingly, no resolution will be put to Shareholders on this item of business.
Resolution 1: Adoption of Remuneration Report
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That for the purpose of section 250R(2) of the Corporations Act 2001 and for all other purposes, the Remuneration
Report (included in the Directors' Report) for the financial year ended 31 December 2020 be adopted.”
Resolution 2: Re-Election of Mr David Segal as a Director of the Company
To consider, and if thought fit, pass the following resolution as an ordinary resolution:
“That Mr David Segal, being a Director who retires by rotation pursuant to the Company’s Constitution and being
eligible for re-election, be re-elected as a Director of the Company.”
Resolution 3: Approval to Grant Options to Dr Gregory Collier (or his nominee)
To consider, and if thought fit, pass the following resolution as an ordinary resolution:
“That, pursuant to and in accordance with ASX Listing Rule 10.14, and for all other purposes, approval be given to
issue under the Company’s Equity Incentive Plan a total of 5,990,465 unlisted options to Dr Gregory Collier (a Director
of the Company), or his nominee, expiring 42 months from date of issue, and having the exercise price, vesting date
and other terms and conditions set out or described in the Explanatory Statement which accompanied and formed
part of the Notice of the Meeting.”
-2-
Resolution 4: Approval to Grant Options to Mr David Segal (or his nominee)
To consider, and if thought fit, pass the following resolution as an ordinary resolution:
“That, pursuant to and in accordance with ASX Listing Rule 10.14, and for all other purposes, approval be given to
issue under the Company’s Equity Incentive Plan a total of 3,993,644 unlisted options to Mr David Segal (Chair and
Director of the Company), or his nominee, expiring 42 months from date of issue, and having the exercise price,
vesting date and other terms and conditions set out or described in the Explanatory Statement which accompanied
and formed part of the Notice of the Meeting.”
Resolution 5: Approval to Grant Options to Dr Ross Murdoch (or his nominee)
To consider, and if thought fit, pass the following resolution as an ordinary resolution:
“That, pursuant to and in accordance with ASX Listing Rule 10.14, and for all other purposes, approval be given to
issue under the Company’s Equity Incentive Plan a total of 3,993,644 unlisted options to Dr Ross Murdoch (a Director
of the Company), or his nominee, expiring 42 months from date of issue, and having the exercise price, vesting date
and other terms and conditions set out or described in the Explanatory Statement which accompanied and formed
part of the Notice of the Meeting.”
Resolution 6: Approval to Grant Options to Mr Matthew McNamara (or his nominee)
To consider, and if thought fit, pass the following resolution as an ordinary resolution:
“That, pursuant to and in accordance with ASX Listing Rule 10.14, and for all other purposes, approval be given to
issue under the Company’s Equity Incentive Plan a total of 3,993,644 unlisted options to Mr Matthew McNamara (a
Director of the Company), or his nominee, expiring 42 months from date of issue, and having the exercise price,
vesting date and other terms and conditions set out or described in the Explanatory Statement which accompanied
and formed part of the Notice of the Meeting.”
Resolution 7: Ratification of Prior Issue of Shares
To consider, and if thought fit, pass the following resolution as an ordinary resolution:
“That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders approve, ratify, and confirm
the allotment and issue on 15 February 2021 of 229,999,999 fully paid ordinary shares in the Company at an issue
price of $0.022 (2.2 cents) per share as described in the Explanatory Statement."
Resolution 8: Ratification of Prior Issue of Options
To consider, and if thought fit, pass the following resolution as an ordinary resolution:
“That for the purposes of ASX Listing Rule 7.4, and for all other purposes, shareholders approve, ratify, and confirm
the issue of up to 115,000,000 Listed Options (exercisable at $0.035 each and expiring on 31 December 2023)
attached to the fully paid ordinary shares issued on 15 February 2021 to institutional and sophisticated investors,
under the terms and conditions set out in the Explanatory Statement.”
Resolution 9: Ratification of Prior Issue of Broker Options
To consider, and if thought fit, pass the following resolution as an ordinary resolution:
“That for the purposes of Listing Rule 7.4 and for all other purposes, shareholders approve, ratify, and confirm the
issue of 7,500,000 Listed Options (exercisable at $0.035 each and expiring on 31 December 2023) on 15 February
2021 to Peak Asset Management (or their nominees) on the terms set out in the Explanatory Statement.”
-3-
SPECIAL BUSINESS
Resolution 10: Approval of 10% Placement Facility
To consider and, if thought fit, to pass the following as a special resolution:
“That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the
issue of Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) calculated in
accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory
Statement.”
BY ORDER OF THE BOARD
Melanie Leydin
Company Secretary
14 April 2021
-4-
NOTES
1.
Entire Notice: The details of the Resolutions contained in the Explanatory Statement accompanying this Notice of Meeting should
be read together with, and form part of, this Notice of Meeting.
2.
Record Date: The Company has determined that for the purposes of the Annual General Meeting, Shares will be taken to be held
by the persons who are registered as holding the shares at 7.00pm (AEST) on the date 48 hours before the date of the Annual
General Meeting. Only those persons will be entitled to vote at the Annual General Meeting and transfers registered after that time
will be disregarded in determining entitlements to attend and vote at the Annual General Meeting.
3.
Proxies
a.
Votes at the Annual General Meeting may be given personally or by proxy, attorney or representative.
b.
Each Shareholder has a right to appoint one or two proxies.
c.
A proxy need not be a shareholder of the Company.
d.
If a Shareholder is a company, it must execute under its common seal or otherwise in accordance with its Constitution or the
Corporations Act.
e.
Where a Shareholder is entitled to cast two or more votes, the shareholder may appoint two proxies and may specify the
proportion of number of votes each proxy is appointed to exercise.
f.
If a Shareholder appoints two proxies, and the appointment does not specify the proportion or number of the Shareholder’s
votes, each proxy may exercise half of the votes. If a Shareholder appoints two proxies, neither proxy may vote on a show of
hands.
g.
A proxy must be signed by the Shareholder or his or her attorney who has not received any notice of revocation of the authority.
Proxies given by corporations must be signed in accordance with corporation’s constitution and Corporations Act.
h.
To be effective, proxy forms must be received by the Company’s share registry (Computershare Investor Services Pty Limited)
no later than 48 hours before the commencement of the Annual General Meeting, this is no later than 1.00pm (AEST) on
Saturday, 29 May 2021. Any proxy received after that time will not be valid for the scheduled Meeting.
4.
Corporate Representative
Any corporate shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that
person with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that company’s
representative. The authority may be sent to the Company and/or share registry in advance of the Meeting or handed in at the
Meeting when registering as a corporate representative.
5.
Voting Exclusion Statement:
Resolution 1
In accordance with sections 250R(4) and 250BD(1) of the Corporations Act, a vote must not be cast (in any capacity, including as
a proxy), and the Company will disregard any votes purported to be cast, on this Resolution by, or on behalf of, a member of the
Key Management Personnel, details of whose remuneration are included in the remuneration report, or a Closely Related Party of
such a member (KMP voter), unless the KMP voter is casting a vote on this Resolution on behalf of a person who is not a KMP
voter (including as a proxy) and either:
(a) the KMP voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution; or
(b) the KMP voter is the Chair of the meeting and the appointment of the Chair as proxy:
a. does not specify the way the proxy is to vote on the Resolution; and
b. expressly authorises the chair to exercise the proxy even if the Resolution is connected directly or indirectly with the
remuneration of a member of the key management personnel for the Company or the consolidated entity.
If you appoint the Chair as your proxy and you do not direct the Chairman how to vote, you will be expressly authorising the Chair
to exercise the proxy even if the relevant Resolution is connected directly or indirectly with the remuneration of a member of the
Key Management Personnel for the Company.
If the Chair of the Meeting is appointed as a proxy for a person who is permitted to vote on this Resolution, the Chair will vote any
proxies which do not indicate on their Proxy Form the way the Chair must vote, in favour of this Resolution. In exceptional
circumstances, the Chair may change his or her voting intention on the Resolution, in which case an ASX announcement will be
made. Shareholders may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
If you purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as indicated above) and
you may be liable for breaching the voting restrictions that apply to you under the Corporations Act.
Resolution 2
There are no voting exclusions on this Resolution.
-5-
Resolutions 3, 4, 5 and 6
The Company will disregard any votes cast in favour of each of these Resolutions (respectively and separately) by or on behalf of:
(a) a person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3 who is eligible to participate in the Company’s Equity Incentive
Plan, being the following directors:
a.
b.
c.
d.
Dr Gregory Collier (or his nominee);
Mr David Segal (or his nominee);
Dr Ross Murdoch (or his nominee); and
Mr Matthew McNamara (or his nominee) or
(b) an associate of that person or those persons.
However, this does not apply to a vote cast in favour of the Resolutions by:
(a)
(b)
(c)
a person as a proxy or attorney for a person who is entitled to vote on the Resolutions, in accordance with directions given to
the proxy or attorney to vote on the Resolution in that way; or
the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the Resolutions, in accordance with a
direction given to the Chair to vote on the Resolutions as the Chair decides; or
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met:
a. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an
associate of a person excluded from voting, on the Resolutions; and
b. the holder votes on the Resolutions in accordance with directions given by the beneficiary to the holder to vote in that
way.
A further restriction also applies to Key Management Personnel and their closely related parties voting undirected proxies on these
Resolutions - see item 6 below.
Resolutions 7 and 8
The Company will disregard any votes cast in favour on these Resolutions by any person who participated in the issue of shares
and any associates of those persons, or any person who is a counterparty to the agreement being approved.
However, this does not apply to a vote cast in favour of a resolution by:
(a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the
proxy or attorney to vote on the resolution in that way; or
(b) the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction
given to the Chair to vote on the resolution as the Chair decides; or
(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
a. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an
associate of a person excluded from voting, on the resolution; and
b. the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Resolution 9
The Company will disregard any votes cast in favour on this Resolution by Peak Asset Management and any associates of Peak
Asset Management, or any person who is a counterparty to the agreement being approved.
However, this does not apply to a vote cast in favour of a resolution by:
(a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the
proxy or attorney to vote on the resolution in that way; or
(b) the Chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction
given to the Chair to vote on the resolution as the Chair decides; or
(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following
conditions are met:
a. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an
associate of a person excluded from voting, on the resolution; and
b. the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
Resolution 10
As at the date of dispatch of this Notice, the Company is not proposing to make an issue of Equity Securities under Listing Rule
7.1A.2 and, therefore, a voting exclusion statement on this resolution is not currently required by Listing Rule 7.3A.7.
-6-
6.
Restrictions on KMPs voting undirected proxies:
A vote must not be cast as proxy on any of Resolution 1 or Resolutions 3 to 6 by a member of the Key Management Personnel (as
defined by the Corporations Act) or a closely related party of Key Management Personnel.
However, a person described above (a “Restricted Voter”) may cast a vote on behalf of a person who is not a Restricted Voter on
any of Resolution 1 or Resolutions 3 to 6 as a proxy if:
(a) The Restricted Voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution(s); or
(b) The Chair is the Restricted Voter and the written appointment of the Chair as proxy does not specify the way the proxy is to
vote on the Resolution(s) and expressly authorises the Chair to exercise the proxy even though the Resolution(s) is or are
connected directly or indirectly with the remuneration of a member of the Key Management Personnel.
If you appoint the Chair as your proxy and you do not direct the Chair how to vote, you will be expressly authorising the Chair to
exercise the proxy even if the relevant Resolution is connected directly or indirectly with the remuneration of a member of the Key
Management Personnel for the Company.
7.
Enquiries
Shareholders are invited to contact the Company Secretary, Melanie Leydin on (03) 9692 7222 if they have any queries in respect
of the matters set out in these documents.
-7-
EXPLANATORY STATEMENT
ORDINARY BUSINESS
Receipt and Consideration of Financial Statements and Reports
A copy of the Annual Report for the financial year ended 31 December 2020 (which incorporates the Company's
Financial Report, Directors Report (including the Remuneration Report and the Auditors Report) is not enclosed
as there is no longer a requirement for the Company to incur the printing and distribution cost associated with
doing so for all Shareholders.
You may obtain a hard copy free of charge by contacting the Company by phone at (03) 9692 7222 and you may
request that this occurs on a standing basis for future years. Alternatively, you may access the Annual Report at
the Company's website: http://avecho.com.au/ or via the Company's announcement platform on ASX.
Except as set out in Resolution 1, no resolution is required on these reports.
Resolution 1: Adoption of Remuneration Report
Background
Section 250R(2) of the Corporations Act requires that a resolution to adopt the Remuneration Report must be put
to the vote at the Annual General Meeting. The vote on this Resolution is advisory only and does not bind the
Directors or the Company.
The Remuneration Report is set out in the Directors’ Report in the Company’s 2020 Annual Report. The
Remuneration Report sets out the Company’s remuneration arrangements for the Directors and senior
management of the Company.
In accordance with Section 250SA of the Corporations Act, Shareholders will be provided with a reasonable
opportunity to ask questions concerning, or make comments on, the Remuneration Report at the Annual General
Meeting.
The Corporations Act requires the Company to put a resolution to Shareholders that in accordance with Division
9 of Part 2G.2 of the Corporations Act, if twenty five (25%) per cent or more of votes that are cast are voted
against the adoption of the Remuneration Report at two consecutive Annual General Meetings, Shareholders will
be required to vote at the second of those Annual General Meetings on a resolution (a “spill resolution”) that
another meeting be held within 90 days at which all of the Company’s Directors (other than the Managing Director)
must go up for re-election.
It is noted that at the Company’s last Annual General Meeting, the votes cast against the Remuneration Report
represented less than twenty-five (25%) per cent of the total votes cast and accordingly, a spill resolution will not
under any circumstances be required for the Annual General Meeting.
The Directors will consider the outcome of the vote and comments made by Shareholders on the Remuneration
Report at the Meeting when reviewing the Company’s remuneration policies.
Board Recommendation
Noting that each Director has a personal interest in their own remuneration from the Company (as such interests
are described in the Remuneration Report) and, as described in the voting exclusions on this Resolution (set out
in the Notice of AGM), that each Director (or any Closely Related Party of a Director) is excluded from voting their
shares on this Resolution, the Board encourage all eligible shareholders to cast their votes in favour of this
Resolution. The Chairman of the meeting intends to vote undirected proxies in favour of this Resolution.
-8-
Voting Exclusions
For voting exclusions refer to Note 5.
Resolution 2: Re-Election of Mr David Segal as a Director of the Company
Background
The Constitution of the Company requires that at every Annual General Meeting, one third of Directors shall retire
from office and provides that such Directors are eligible for re-election at the meeting. Mr David Segal, being
eligible, offers himself for re-election.
Mr Segal was appointed as a Non-Executive Director on 19 May 2016.
Mr Segal was the Investor Relations Manager of the Company from 2011 to 2015. He worked in stockbroking for
over 30 years, where he set up and raised capital for and ran Trent Securities which was absorbed into Shaw
Stockbroking in 1992. Mr Segal has been a shareholder of the Company since 1999 and has a close rapport with
many shareholders whom he engaged with in his role as Investor Relations Manager or as an investment adviser
at Shaw Stockbroking. He has a Law and Commerce degree from Melbourne University and is a Graduate of the
Australian Institute of Company Directors.
Board Recommendation
The Board (with Mr Segal abstaining) recommends that Shareholders vote in favour of this Resolution. The Chair
of the Meeting intends to vote undirected proxies in favour of Mr Segal’s re-election.
Voting Exclusions
There are no voting exclusions on this Resolution.
Resolutions 3, 4, 5 and 6: Approval to Grant Options to the Directors (or their nominees)
Background
Resolutions 3 to 6 provide for a total of up to 17,971,397 unlisted options (“the Options”) being granted under the
Company’s Equity Incentive Plan (the Plan), previously approved by shareholders on 13 July 2020, to the four
Non-Executive Directors of the Company (or their respective nominees) as described below:
Director (or nominee)
Number of
Options
5,990,465
3,993,644
3,993,644
3,993,644
17,971,397
Dr Gregory Collier
Mr David Segal
Dr Ross Murdoch
Mr Matthew McNamara
Total
The Options have an exercise price of $0.0169 (1.69 cents) each and will expire 42 months from date of issue.
The Options will vest in four tranches, as detailed below:
a) Tranche 1: 25% of the Options to vest on or about the 28 May 2021 (“Date of Issue”), but no later than one
month after the date of the meeting.
b) Tranche 2: 25% of the Options to vest 12 months from Date of Issue
c) Tranche 3: 25% of the Options to vest 23 months from Date of Issue
d) Tranche 4: 25% of the Options to vest 36 months from Date of Issue
-9-
The Options will vest subject to service conditions being met on the vesting date unless a change in employment
terms has been agreed in writing with the Company regarding the treatment of unvested Options where they
cease to be Directors prior to the vesting date.
A summary of the material terms of the Options and Equity Incentive Plan are respectively set out in Annexure
A and B.
Directors’ Remuneration Packages and Interests
As at the date of this Notice, the details (including the amount) of the current total remuneration package of each
of the Directors to whom (or to whose nominees) Options would be issued if Resolutions 3, 4, 5 and 6 are passed
are:
Director (or nominee)
Dr Gregory Collier
Mr David Segal
Dr Ross Murdoch
Mr Matthew McNamara
Remuneration Package Details (excluding the proposed Options)
A$100,000 per annum
A$55,000 per annum
A$55,000 per annum
A$55,000 per annum
Management has prepared an assessment of the indicative fair value of the Options as summarised below. The
value is indicative only, based on assumptions relevant at the date of the calculation, being 31 December 2020.
Different assumptions may be relevant at issue date which may alter the value of the Options for financial reporting
purposes. The total remuneration packages in the above table would be increased for each of the above Directors
by the total per Director set out in the following table, based on the assumptions. The actual valuation amount
will not be able to be calculated until the Options are issued, when the exercise price will be known (at which time
other assumptions may also have changed).
Assessment:
Indicative fair value per Option
Number of Options per Director (except for Dr Gregory Collier)
Number of Options for Dr Gregory Collier
Total $ per Director (except for Dr Gregory Collier)
Total $ for Dr Gregory Collier
Total Options
Total $
$0.02715
3,993,644
5,990,465
$108,427
$162,641
17,971,397
$271,068
The indicative fair value was calculated using the Binomial valuation model. The assumptions used in the valuation
model were as follows:
Assumptions:
Valuation Date
Spot price
Exercise Price
Expiry Date
Risk Free Rate
Volatility
31 December 2020
$0.0290
$0.0169*
42 months from date of issue
0.10%
188%
*Based on 45% premium of a 30-day VWAP immediately prior to 2 November 2020, with the last trading day being 30 October 2020.
- 10 -
As at the date of this Notice, the Directors who are proposed to receive the Options have the following direct and
indirect interests in shares and/or options of the Company:
Director/Shareholder
(and/or associates)
Existing Shares
Existing unlisted options
Dr Gregory Collier
2,000,000 (0.13%)
Mr David Segal
18,491,281 (1.16%)
2,250,000 at an exercise
price of $0.023 each
1,500,000 at an exercise
price of $0.023 each
Nil
Nil
Dr Ross Murdoch
Mr Matthew McNamara
1,666,667(0.10%)
Nil (0%)
Number of securities
issued under the current
Equity Incentive Scheme
Nil
Nil
Nil
Nil
Following issue of the Options, each of the Directors in the above table (or their respective nominees) would hold
the following securities in the Company:
Director/Shareholder
(and/or associates)
Dr Gregory Collier
Mr David Segal
Dr Ross Murdoch
Mr Matthew McNamara
Existing Shares
Options
Holding if options exercised*
2,000,000 (0.13%)
18,491,281 (1.16%)
1,666,667(0.10%)
Nil (0%)
6,243,644
5,493,644
3,993,644
3,993,644
8,243,644 (0.52%)
23,984,925 (1.50%)
5,660,311 (0.35%)
3,993,644 (0.25%)
*Based on the assumptions that Directors will exercise all their Options and that the issued capital remain unchanged at 1,598,894,680 Shares.
Corporations Act
The Board has formed the view that the issues of Options to the above Directors (or their respective nominees)
do not require Shareholder approval under section 208 of the Corporations Act as the issues constitute
“reasonable remuneration” in accordance with section 211 of the Corporations Act.
A “financial benefit” is defined in section 229 of the Corporations Act and includes granting an option to a related
party.
Section 228 of the Corporations Act defines a “related party” for the purposes of Chapter 2E to include:
• directors of the public company (section 228(2)(a)); and
• an entity controlled by directors of the public company (section 228(4)). Section 228(5) provides that an entity
is a related party of a public company at a particular time if the entity was a related party of the public company
of a kind referred to in subsection (1), (2), (3) or (4) at any time within the previous 6 months.
In reaching this view, the Board considers the proposed grant of Options aligns the interests of each of the above
Directors with the interests of Shareholders. The grant of Options to each of the above Directors is a cost-effective
form of remuneration when compared to the payment of cash consideration.
Consistent with the desire to minimise cash expenditures, the Board believes that having regard to the Company's
current cash position, and the Company’s objective to use available cash to fund its operations in the near future,
and in order to compensate the above Directors in line with current market practices, Options provide an
appropriate and meaningful remuneration component to the above Directors that is aligned with Shareholder
interests.
If Resolutions 3 to 6 are passed and the Options are issued, each of the Directors proposed to receive Options
under these Resolutions (including direct and indirect interests) will have a relevant interest in the Company’s
securities, as set out earlier.
- 11 -
Listing Rule 10.14
The Company is proposing to make issues of the Options as set out above (the “Issues”) under the Plan, which
is an employee incentive scheme as defined in the Listing Rules.
Listing Rule 10.14 provides that a listed company must not permit any of the following persons to acquire equity
securities under an employee incentive scheme:
•
•
•
10.14.1: a director of the company;
10.14.2: an associate of a director of the company; or
10.14.3: a person whose relationship with the company or a person referred to in Listing Rule 10.14.1 or
10.14.2 is such that, in ASX’s opinion, the acquisition should be approved by its shareholders,
unless it obtains the approval of its shareholders.
The Issues fall within Listing Rules 10.14.1 and/or 10.14.2 above and therefore require the approval of the
Company’s shareholders under Listing Rule 10.14. Resolutions 3 to 6 seek the required shareholder approvals
to the issues under and for the purposes of List
Share your feedback
Discover